


Brahmer J, Horn L, Jackman D, et al. CT077 - Five-year follow-up from the phase II CheckMate 012 study. Presented at: American Association for Cancer Research Annual Meeting; April 3, 2017; Washington, DC.


Galsky MD, Retz M, Sieker-Radike AQ, et al. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study. Presented at: European Society for Medical Oncology Annual Meeting; Abstract LBA31-PR; October 7-11, 2016; Copenhagen, Denmark.


Hammers HJ, Plimack E, Infante J, et al. Updated results from a phase I study of nivolumab (NIVO) in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC): The CheckMate016 study. Presented at: European Society for Medical Oncology Annual Meeting; Abstract 1062P; October 7-11, 2016; Copenhagen, Denmark.


Hodi S, Postow MA, Chesney JA, et al. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate069). Presented at: American Society of Clinical Oncology Annual Meeting; Abstract 9518; June 3-7, 2016; Chicago, IL.


Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate067). Presented at: American Association for Cancer Research Cancer Annual Meeting; Abstract 2075; April 18, 2017; Washington, DC.


NCT01873454; April 3, 2017; Washington, DC. Presented at: American Association for Cancer Research Annual Meeting; Abstract CT075; April 3, 2017; Washington, DC.

Orlando, FL. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; Abstract 200; February 16-18, 2017; Orlando, FL.


Rosenberg JE, Bono P, Kim J, et al. Nivolumab monotherapy in metastatic urothelial carcinoma (mUC): Updated efficacy by subgroup and safety results from the CheckMate032 study. Presented at: European Society for Medical Oncology Annual Meeting; Abstract 784; October 7-11, 2016; Copenhagen, Denmark.


Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)–positive NSCLC. Presented at: European Society for Medical Oncology Annual Meeting; Abstract LBA7_PR; October 7-11, 2016; Copenhagen, Denmark.